Rapt Therapeutics (RAPT) Competitors $10.61 +1.89 (+21.67%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$10.50 -0.11 (-1.04%) As of 07/15/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RAPT vs. ORGO, MAZE, OPT, TYRA, TLRY, ABVX, TSHA, PRME, ORKA, and BCYCShould you be buying Rapt Therapeutics stock or one of its competitors? The main competitors of Rapt Therapeutics include Organogenesis (ORGO), Maze Therapeutics (MAZE), Opthea (OPT), Tyra Biosciences (TYRA), Tilray Brands (TLRY), Abivax (ABVX), Taysha Gene Therapies (TSHA), Prime Medicine (PRME), Oruka Therapeutics (ORKA), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. Rapt Therapeutics vs. Its Competitors Organogenesis Maze Therapeutics Opthea Tyra Biosciences Tilray Brands Abivax Taysha Gene Therapies Prime Medicine Oruka Therapeutics Bicycle Therapeutics Organogenesis (NASDAQ:ORGO) and Rapt Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends. Does the media refer more to ORGO or RAPT? In the previous week, Rapt Therapeutics had 7 more articles in the media than Organogenesis. MarketBeat recorded 12 mentions for Rapt Therapeutics and 5 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.96 beat Rapt Therapeutics' score of 0.38 indicating that Organogenesis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Rapt Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, ORGO or RAPT? Organogenesis has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, Rapt Therapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500. Which has stronger earnings & valuation, ORGO or RAPT? Organogenesis has higher revenue and earnings than Rapt Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Rapt Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganogenesis$482.04M1.06$860K-$0.17-23.71Rapt Therapeutics$1.53M114.70-$129.87M-$19.20-0.55 Do insiders & institutionals have more ownership in ORGO or RAPT? 49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 99.1% of Rapt Therapeutics shares are owned by institutional investors. 33.0% of Organogenesis shares are owned by company insiders. Comparatively, 6.6% of Rapt Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer ORGO or RAPT? Organogenesis presently has a consensus price target of $6.50, suggesting a potential upside of 61.29%. Rapt Therapeutics has a consensus price target of $19.80, suggesting a potential upside of 86.62%. Given Rapt Therapeutics' higher possible upside, analysts plainly believe Rapt Therapeutics is more favorable than Organogenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Rapt Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Is ORGO or RAPT more profitable? Rapt Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -3.46%. Organogenesis' return on equity of -4.00% beat Rapt Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Organogenesis-3.46% -4.00% -2.26% Rapt Therapeutics N/A -81.47%-70.24% SummaryOrganogenesis beats Rapt Therapeutics on 9 of the 15 factors compared between the two stocks. Get Rapt Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPT vs. The Competition Export to ExcelMetricRapt TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$144.20M$2.96B$5.62B$9.30BDividend YieldN/A2.43%4.25%4.03%P/E Ratio-0.5520.2228.5719.58Price / Sales114.70291.25423.3093.84Price / CashN/A43.1536.0257.93Price / Book0.927.568.135.54Net Income-$129.87M-$55.11M$3.24B$257.73M7 Day Performance25.71%3.81%0.16%-0.08%1 Month Performance28.76%11.60%5.95%8.09%1 Year Performance-64.63%-2.11%26.09%13.02% Rapt Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPTRapt Therapeutics4.3805 of 5 stars$10.61+21.7%$19.80+86.6%-62.9%$144.20M$1.53M-0.5580News CoverageAnalyst RevisionGap UpTrading HaltedHigh Trading VolumeORGOOrganogenesis4.4729 of 5 stars$4.25flat$6.00+41.2%+39.4%$539.11M$482.04M-25.00950News CoverageAnalyst ForecastMAZEMaze TherapeuticsN/A$12.12+5.4%$25.67+111.8%N/A$530.82M$167.50M0.00121OPTOpthea0.3874 of 5 stars$3.41+7.2%$1.33-60.9%+63.2%$524.83M$120K0.008Gap UpTYRATyra Biosciences3.1086 of 5 stars$9.61-3.9%$30.83+220.8%-49.5%$510.20MN/A-5.9020TLRYTilray Brands1.8712 of 5 stars$0.50-6.6%$1.92+280.7%-68.9%$506.67M$788.94M-0.482,650ABVXAbivax2.2368 of 5 stars$7.95-0.1%$31.00+289.9%-35.6%$504.46MN/A0.0061News CoveragePositive NewsHigh Trading VolumeTSHATaysha Gene Therapies3.997 of 5 stars$2.34-4.5%$8.20+250.4%+2.9%$502.30M$8.33M-6.88180PRMEPrime Medicine3.7295 of 5 stars$3.80+22.2%$10.08+165.4%-25.8%$498.92M$3.85M-1.85234High Trading VolumeORKAOruka Therapeutics2.8913 of 5 stars$13.29+5.5%$40.38+203.8%N/A$497.58MN/A-2.95N/ANews CoveragePositive NewsBCYCBicycle Therapeutics3.3819 of 5 stars$7.17-3.5%$25.00+248.7%-66.0%$496.52M$35.28M-2.28240 Related Companies and Tools Related Companies Organogenesis Competitors Maze Therapeutics Competitors Opthea Competitors Tyra Biosciences Competitors Tilray Brands Competitors Abivax Competitors Taysha Gene Therapies Competitors Prime Medicine Competitors Oruka Therapeutics Competitors Bicycle Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPT) was last updated on 7/16/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapt Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapt Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RAPT Stock Alerts